# Syntensor

> Syntensor builds frontier AI foundation models for cellular biology and human genetics that simulate how drugs act inside the body before a single patient is dosed. Using dynamical systems simulation and neural differential equations over multi-omics data, its platform predicts drug efficacy, systemic toxicity, and the causes of clinical trial failure, then explains the mechanism behind each prediction. Founded out of the University of Cambridge and now headquartered in San Francisco, the company aims to build an accurate, interpretable mechanistic model of human physiology that de-risks pharmaceutical R&D.

- **Founded:** 2019
- **Headquarters:** San Francisco, United States
- **Founders:** Clayton Rabideau (Founder & CEO (PhD, Chemical Engineering & Biotechnology, University of Cambridge)), Rosie Higgins (Co-founder & COO (former COO at BenevolentAI, former VP at Novartis))
- **Team size:** ~11 employees
- **Products:** Biological systems simulator, Drug efficacy & toxicity prediction, Genomics foundation models, Mechanism & interpretability layer
- **Notable:** Raised over $4.2M via a 2024 Republic equity crowdfunding campaign against a ~$20M valuation cap., Backed by Lifeforce Capital, Hula, and Morningside., Established research collaborations with the University of Michigan, Mila, and Stanford.

## Products & services

- **Biological systems simulator** — A platform that uses dynamical systems simulation and neural differential equations to model how chemical perturbations propagate through cell signaling pathways, simulating cellular assays and preclinical endpoints in silico.
- **Drug efficacy & toxicity prediction** — Models that predict drug efficacy indicators, toxicity endpoints, and pathway activation from cell-line and compound data, aimed at forecasting the drivers of clinical trial success or failure.
- **Genomics foundation models** — Large-scale representation learning over multi-omics and human genetic data for gene expression prediction and trait prediction from genomes.
- **Mechanism & interpretability layer** — Explainable, neurosymbolic outputs that generate causal hypotheses and visualize a drug's mechanism of action rather than returning black-box scores.

## Achievements

- Raised over $4.2M via a 2024 Republic equity crowdfunding campaign against a ~$20M valuation cap.
- Backed by Lifeforce Capital, Hula, and Morningside.
- Established research collaborations with the University of Michigan, Mila, and Stanford.
- Founded out of University of Cambridge computational synthetic biology research.
- Reported drug-response / clinical-outcome prediction accuracy of over 80% in company materials (approximate, self-reported).

## Latest updates

- **2024-01** — Closed a Republic equity crowdfunding campaign raising over $4.2M at an approximately $20M valuation cap.
- **2024-01** — Positioned around foundation models for cellular biology and the 'virtual cell', expanding multi-omics and genomics work.

## Links

- Website: https://syntensor.com
- LinkedIn: https://www.linkedin.com/company/syntensor
- GitHub: https://github.com/synthetic-tensors

---

Profile page: https://yespress.io/syntensor
Published by YesPress — https://yespress.io
Last updated: 2026-07-02